Medicus Pharma Ltd.最新披露的预设扩展二期临床试验Sknjct-003数据分析结果证实,其研究药物存在明确的剂量-效应关系。该数据进一步验证了治疗方案的有效性,为后续临床开发提供重要依据。
Medicus Pharma Ltd.最新披露的预设扩展二期临床试验Sknjct-003数据分析结果证实,其研究药物存在明确的剂量-效应关系。该数据进一步验证了治疗方案的有效性,为后续临床开发提供重要依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.